Onco Actu du 30 juin 2015

	2. Etiologie
Citrus Fruit Consumption May Be Associated With Increased Melanoma Risk [ASCO] “This study adds to the growing discussion around food and cancer risk. While the findings are intriguing, it’s far too soon to recommend any broad changes to grapefruit or orange consumption. Until conclusive data are available, we should continue to be cautious about protecting our skin from sun exposure.”
Citrus fruit linked with melanoma in preliminary study [Reuters] Melanoma risk increased as citrus consumption increased, rising to a 36 percent increase in risk for people who ate the fruits more than 1.5 times per day, on average. Of the citrus fruits, grapefruit seemed to have the strongest association with melanoma.
	3.5 Prévention - UV
Act Now to Prevent Skin Cancer Later [CANCER RESEARCH Catalyst] The authors of the CDC report calculated that nationwide implementation of a comprehensive skin cancer prevention program, like the highly successful SunSmart program in Victoria, Australia, could prevent about 230,000 melanoma cases between 2020 and 2030, and that this would result in savings of $2.7 billion in initial year treatment costs.
	5. Traitements
Depersonalized Medicine Shows Promising Results against Cancer [GEN] Unlike recent advances in personalized medicine that focus on specific genetic mutations associated with different types of cancer, this research targets a broad principle that applies to almost every kind of cancer: its energy source.
No easy road to outsmart cancer [Cancer World] It’s astonishing and frightening that new drugs are being approved based on these “failed surrogates” and small phase II trials. We can only hope that these rushed decisions won’t do our patients more harm than good.
	5.12 Immunothérapies
Arming T Cells with Homing Devices [Celgene] With CAR technology, excitement looms over potential “fifth pillar” of cancer treatments.
	5.2 Pharma
Juno Announces FDA Acceptance of Investigational New Drug Application for JCAR017 in Relapsed/Refractory B Cell Non-Hodgkin Lymphoma [Juno Therapeutics] The IND enables Juno to initiate a multi-center Phase I trial exploring JCAR017 for r/r NHL, scheduled to begin in 2015, with the potential to advance to a registration trial in 2016.
Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy [Merck] The primary endpoint of the study was complete response (CR) (as measured by no vomiting and no use of rescue medication for nausea or vomiting) in the delayed phase (25 to 120 hours following initiation of chemotherapy).
	5.2.1 Pharma - Partenariats
Celgene To Pay $1B For A Big Piece of Juno and T Cell Therapies [Xconomy] The partnership will cut both ways. Juno gains the right to license undisclosed Celgene programs that target T cells. The companies will share costs and profits on those programs, with Celgene responsible for 70 percent and Juno 30 percent.
Celgene pays $1B in landmark deal to buy into Juno's pipeline of CAR-T drugs [FierceBiotech] The pact leaves Celgene in a unique position in the cancer field, noting its recent $450 million deal to partner with AstraZeneca ($AZN) on its PD-L1 program.
Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma [Lilly] Under the terms of the agreement, Immunocore and Lilly will conduct a Phase Ib/II clinical study evaluating the safety and preliminary efficacy of IMCgp100 in combination with galunisertib in metastatic cutaneous melanoma. A second Phase Ib/II study will be conducted combining IMCgp100 with merestinib in metastatic uveal melanoma.
Celgene and Juno Announce Ten-Year Collaboration to Advance Potentially Groundbreaking Immunotherapies for Patients with Cancer and Autoimmune Diseases [Celgene] Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno's oncology and cell therapy auto-immune product candidates, including Juno's CD19 and CD22 directed CAR-T product candidates.
Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership [TheStreet] Investors will undoubtedly raise questions about the high price paid by Celgene to get into bed with Juno, especially since CAR-T therapies are still years from the market in certain blood cancers and may never be an effective treatment for solid tumors.
Celgene to invest $1 billion in Juno to partner in cancer therapies [Reuters] The biotech companies, in a conference call to discuss the multi-faceted deal, said they anticipate potential product approvals in 2020.
	5.3 Traitements - FDA, EMA,...
Update on publication of clinical data [EMA] EMA's policy on publication of clinical data entered into force on 1 January 2015 and applies to clinical reports contained in all marketing-authorisation applications submitted on or after this date. The first reports will be published as soon as a decision on the application has been taken, currently foreseen for mid-2016.
	6.1 Observation
Bowel surgery death rate warning [BBC News] Too many patients are dying following emergency bowel surgery, experts who have done a comprehensive audit of care across England and Wales warn.
	6.11 Patients
Michael Douglas: I was sorry for effect oral sex cancer comments had on my wife [The Guardian] In 2013, the two-time Oscar-winner revealed to Xan Brooks of the Guardian that his illness was the result of contracting human papillomavirus (HPV), which experts believe can be brought on by cunnilingus. The story made headlines around the world when Douglas was promoting his Emmy-winning role in Liberace biopic Behind the Candelabra after being declared free of cancer.
	6.6 Publications
American Association for Cancer Research Journals Receive Top Rankings in 2015 Report [AACR] For the 19th consecutive year, Cancer Research ranked first among oncology journals in the number of total citations, with approximately 143,000.
Cancer Discovery's Impact Factor Rises to 19.453 in 2015 [AACR] The journal ranked fifth out of 211 oncology journals, according to the latest Journal Citation Report from Thomson Reuters.
	6.7.3 DMP
How to Take Charge of Your Medical Records [Wall Street Journal] Patients have a lot to gain by getting access to their health information. They just need to know where to get it—and what to do with it.